Search Within

Dana Elizabeth Rathkopf

  1. "Urology"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (10)
Groups
  1. Department of Medicine (22)
  2. Genitourinary Oncology Service (22)
  3. Solid Tumor Oncology Division (22)
  4. Surgery (22)
  5. Urology (22)
  6. Department of Pathology and Laboratory Medicine (11)

More Groups

People
  1. Howard Scher (12)
  2. Brett Carver (11)
  3. Vincent Laudone (10)
  4. Anuradha Gopalan (9)
  5. Susan Slovin (8)
  6. Wassim Abida (8)

More People

Years
  1. 2024 (4)
  2. 2023 (2)
  3. 2021 (2)
  4. 2020 (4)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer (2)
  3. Cancer Research (2)
  4. Annals of Oncology (1)
  5. British Journal of Cancer (1)
  6. Cancer Cell (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (3)
  3. Cell Press (2)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. Wiley Blackwell (2)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P. T.; Wagner, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
    Journal Article

    McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D.; Laudone, V. P.; Bubley, G. J.; Einstein, D. J.; Chang, P.; Wagner, A. A.; more...
    Cancer (2024)

    Fulltext@MSK | Save
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P.; Wagner, A.; Kane, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer
    Journal Article

    Truong, H.; Breen, K.; Nandakumar, S.; Sjoberg, D. D.; Kemel, Y.; Mehta, N.; Lenis, A. T.; Reisz, P. A.; Carruthers, J.; Benfante, N.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer
    Journal Article

    McKay, R. R.; Xie, W.; Ye, H.; Fennessy, F. M.; Zhang, Z.; Lis, R.; Calagua, C.; Rathkopf, D.; Laudone, V. P.; Bubley, G. J.; more...
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis
    Meeting Abstract

    Zhao, J. L.; Zaidi, S.; Chan, J.; Wadosky, K.; Karthaus, W.; Choi, D.; Agudelo Rivera, A.; Gopalan, A.; Rathkopf, D.; Carver, B.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save